

Influence of Apo E Polymorphism on Coronary Artery Disease

S. Fallah, M. Seifi, M. Firoozrai, T. Godarzi, M. Jafarzadeh, and L. H. Ghohari

Abstract—The ϵ_4 allele of the ϵ_2 , ϵ_3 and ϵ_4 protein isoform polymorphism in the gene encoding apolipoprotein E (Apo E) has previously been associated with increased cardiac artery disease (CAD); therefore to investigate the significance of this polymorphism in pathogenesis of CAD in Iranian patients with stenosis and control subjects. To investigate the association between Apo E polymorphism and coronary artery disease we performed a comparative case control study of the frequency of Apo E polymorphism in One hundred CAD patients with stenosis who underwent coronary angiography (>50% stenosis) and 100 control subjects (<10% stenosis). The Apo E alleles and genotypes were determined by polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP). We observed an association between the Apo E polymorphism and CAD in this study. These data suggest that the Apo ϵ_4 and ϵ_2 alleles increase the risk for CAD in Iranian population ($\chi^2=4.26$, $p=0.05$, $OR=2$ and $\chi^2=0.38$, $p=0.53$, $OR=1.2$). These results suggest that ϵ_4 and ϵ_2 alleles are risk factors for stenosis.

Keywords—Arterial blood vessels, atherosclerosis, cholesterol.

I. INTRODUCTION

A LIPOPROTEIN E is a plasma protein that serves as a ligand for low density lipoprotein receptors and through its interaction with these receptors participates in the transport of cholesterol and other lipids among various cells of the body [1]. Apo E is an exchangeable protein which acts as ligand for low density lipoprotein (LDL) receptors. It also has a repair function in response to tissue injury. It plays an essential role in lipid metabolism, especially in removal atherogenic remnants of triglyceride rich lipoproteins [1-2] and by reversing cholesterol transport in plasma and intercellular lipid transport within tissues. The human Apo E gene is 3.7 Kb including 4 exons and 3 introns (3-4) and is mapped on the short arm of chromosome 19[3-4]. The mature protein is composed of 299 amino acids i.e. 34 KD with several functional domains [4 -7]. The three common isoforms of Apo E2, E3 and E4 are encoded by the Apo ϵ_2 , ϵ_3 and ϵ_4 genes, respectively [6] that give rise to different genotypes (ϵ_2/ϵ_2 , ϵ_3/ϵ_3 ,

ϵ_4/ϵ_4 , ϵ_2/ϵ_4 , ϵ_2/ϵ_3 and ϵ_3/ϵ_4). The primary sequence of these proteins is identical except at amino acids 112 and 158, where there can be cysteines (E2), arginines (E4) and arginine at position 158 (E3) [6]. Apo E2 has a lower binding affinity to LDL receptor (1% of the Apo ϵ_3 binding affinity), whereas the binding affinity of E4 to the LDL receptor is higher [7]. The genetic variations at Apo E have been shown to affect on lipid and lipoprotein levels in the general population [8-9]. The ϵ_4 isoform is associated with increased levels of total cholesterol (TC) and beta lipoprotein [1] and increased susceptibility [11]. A number of studies have investigated association between genetic susceptibility factor for cardiac heart disease (CHD) or atherosclerosis in diverse ethnic populations [12]. The knowledge of lipid profile may predict the potential victims of cardiovascular disease before its initiation and progression and offer the opportunity for primary prevention. Therefore it is very important to identify factors that may influence blood lipid concentrations. The correlation of the most common Apo E polymorphism with CHD has been extensively investigated in the last three decades [2]. A Meta analysis of 48 diseases [13] showed that the Apo ϵ allele is a significant risk factor for CHD. On the other hand a trend for the ϵ_4 allele to be associated with a higher prevalence of target organ damage in patients with mild to moderate hypertension has been proposed [14]. Therefore the current study specially aimed to find whether genetic polymorphism in Apo E gene is a risk factor for CHD in a population from Tehran Iran.

II. MATERIALS AND METHODS

A. Study Subjects

The study group consisted of 100 patients (74 males, 25 females, mean age 58.61 ± 9.35) who were admitted to the cardiology unit of Shahid Rajaee Hospital who had been diagnosed to have atherosclerosis. The diagnosis was based on the complete physical and clinical examination of patients by the cardiologist followed by investigation. For the present study, only patients with atherosclerosis were included while patients with Alzheimer's disease, pulmonary, renal, hepatic disease, cardiomyopathy congestive heart failure and acute myocardial infarction were excluded.

Random were included study as control (64 males, 36 females mean age 53.45 ± 9.35). Control subjects were also similarly evaluated the confounding risk factors included smoking and alcohol consumption, dyslipidemia and family history of atherosclerosis. In the present study, evaluation of the contribution of confounding risk factors of the

S. Fallah, M. Firoozrai, L. H. Ghohari are with Biochemistry Department of Medicine Faculty, Iran University of Medical Sciences, P. O. Box No: 1449614525 Tehran, Iran

M. Seifi, T. Godarzi, M. Jafarzadeh are with Iran University of Medical Sciences, P. O. Box No: 1449614525, Tehran, Iran.

S. Fallah, Associated Prof., is with Biochemistry Department of Medicine Faculty, Iran University of Medical Sciences, P. O. Box No: 1449614525 Tehran, Iran (corresponding phone: (98)21- 88058742 (Ext. 3116); fax: (98)21- 88058742; e-mail: fauhsoudi@iums.ac.ir).

development of arthrosclerosis was based on the individual's personal history findings.

B. Genetic Analysis

Leucocytes extracted following standard protocols [15] DNA was amplified by PCR in a DNA cycler (0005.416model T-cy grady) using oligonucleotide primer forward (5'-ACAGAATTCGCCCCGGCCTGGTACAC3') and reverse (5'-TAAGCTTGCCACGGCTGCCAAGCA 3') (company) as described by Hixson et al [16]. The PCR condition included on initial step of 95° C for 30 min, followed by 33 cycles (95° C 30 S, 55° C 30 S and 70° 1 min) and by a final extension (70° C, 7 min) with 94° C hold according to a protocol described by Hixson et al [16]. Electrophoresis of amplified products (244 bp) was performed on 10% polyacrylamide gel. After PCR implication 5 units of HhaI enzyme (New England Biolabs) was added directly to each reaction mixture for digestion of Apo E sequence of PCR product (over night, 37°C)[16]. Each reaction mixture was loaded onto a 10% polyacrylamide gel and electrophoresed. After electrophoresis, digested fragments were visualized by UV illumination. The size of Hha I fragments were estimated by comparison with known DNA (Fermenta, Gene Ruler 50bp DNA Ladder). Statistically analysis: Allele frequencies were deduced from genotype frequencies, and the Hardy-Weinberg equilibrium was analyzed through the chi-square test. $p < 0.05$ was considered significant. Quantitative information was expressed as mean standard deviation. All calculations were performed by using the SPSS 11.5 program. To evaluate the association of Apo E polymorphism with arthrosclerosis: Multiple logistic regressions were used with maximum likelihood estimation of the regression coefficients and their standard error. Multivariate adjusted odd ratios calculated for Apo ϵ_4 allele (ϵ_4/ϵ_4 and ϵ_3/ϵ_4), ϵ_2 allele (ϵ_2/ϵ_2 , ϵ_2/ϵ_3 and ϵ_2/ϵ_4) and taking allele ϵ_3 (ϵ_3/ϵ_3) as reference. For each odds ratios we calculated two tailed p values and 95% confidence interval 1.2 to 3.8, $p \leq 0.05$ in all.

III. RESULTS

In this study we identified three Apo alleles ϵ_2 , ϵ_3 and ϵ_4 and six genotypes ϵ_4/ϵ_4 , ϵ_3/ϵ_4 , ϵ_2/ϵ_2 , ϵ_2/ϵ_3 , ϵ_2/ϵ_4 and ϵ_3/ϵ_3 . In study population for both men and women, allele frequencies did not deviate from Hardy-Weinberg equilibrium. The distribution of Apo E genotypes in patient subjects differed significantly from control group. As it shown in Table I, the prevalence of six genotypes ϵ_4/ϵ_4 , ϵ_3/ϵ_4 , ϵ_2/ϵ_2 , ϵ_2/ϵ_3 , ϵ_2/ϵ_4 and ϵ_3/ϵ_3 in patient and control 30%, 4%, 8%, 18%, 6%, 34% and 15%, 6%, 12%, 8%, 8% 51% respectively. It observed that the prevalence of ϵ_3/ϵ_4 was 1.5 fold high in patient subjects (4% Vs 6%) when compared with controls ($\chi^2 = 0.42$, $p = 0.156$, OR=0.58). While prevalence ϵ_2/ϵ_3 and ϵ_4/ϵ_4 genotypes were higher in patients (18% Vs 8% and 30% Vs 15%) than in controls ($\chi^2 = 4.3$, $p = 0.036$, OR= 2.52) and ($\chi^2 = 6.4$, $p = 0.01$, OR= 1.86) respectively. The frequency of ϵ_2/ϵ_4 ($\chi^2 = 0.3$, $P = 0.57$, OR=0.49) and ϵ_2/ϵ_2 ($\chi^2 = 0.89$, $p = 0.346$, OR= 0.57) in control was 1.3 and 1.5 fold high when compared with patient subjects (6% Vs 8%) and (8% Vs 12%) respectively. Statistically significant difference was not found between

patients and controls (32% Vs 28%) with respect to ϵ_2 and allele frequency ($\chi^2 = 0.38$, $p = 0.53$, OR=1.2) while ϵ_3 allele frequency was found to be much more prevalent in patients (34% Vs 51%) than in control ($\chi^2 = 5.9$, $P = 0.015$, OR=0.44). As it shown in Table II the prevalence of ϵ_4 allele in patient subjects (34% Vs 21%) is higher than controls ($\chi^2 = 4.23$, $p = 0.04$, OR=2).

TABLE I
PREVALENCE OF APO E GENOTYPES IN CARDIAC HEART DISEASE AND CONTROLS

Genotype	Patient	Control	χ^2	P value	OR
ϵ_3/ϵ_3	34	51	5.9	0.015	0.4
ϵ_4/ϵ_4	30	15	6.4	0.01	1.86
ϵ_3/ϵ_4	4	6	0.42	0.156	0.58
ϵ_2/ϵ_3	18	8	4.3	0.036	2.52
ϵ_2/ϵ_2	8	12	0.89	0.346	0.57
ϵ_2/ϵ_4	6	8	0.3	0.57	0.49

TABLE II
PREVALENCE OF APO E ALLELES IN CARDIAC HEART DISEASE AND CONTROLS

Alleles	Patient	Control	χ^2	P value	OR
ϵ_3	34	51	5.9	0.015	0.44
ϵ_4	34	21	4.23	0.04	2
ϵ_2	32	28	0.38	0.53	1.2

$\epsilon_3 = (\epsilon_3/\epsilon_3)$, $\epsilon_2 = (\epsilon_2/\epsilon_2, \epsilon_2/\epsilon_3 \text{ and } \epsilon_2/\epsilon_4)$ $\epsilon_4 = (\epsilon_4/\epsilon_4 \text{ and } \epsilon_3/\epsilon_4)$

IV. DISCUSSION

Studies conducted in different parts of the globe reveal that gene frequencies at Apo E locus are highly heterogeneous between the populations. The ϵ_3 is the most common form of the gene in most of the population [17-18]. In a population-based study Venkutamana et al [19] reported that the allele frequencies in Indian population 85%-92% for ϵ_3 allele, 3.9% for ϵ_4 allele and 3.5% for ϵ_2 allele. In the present study Apo ϵ allele frequencies in the control group of Tehran population are 34%, 34% and 32% for ϵ_4 , ϵ_3 and ϵ_2 respectively which are not comparable with the study of Venkutamana et al and others [19]. The prevalence of ϵ_2/ϵ_2 , ϵ_2/ϵ_3 , ϵ_2/ϵ_4 , ϵ_3/ϵ_3 , ϵ_3/ϵ_4 , and ϵ_4/ϵ_4 in Korean adults were 0.3%, 10.3%, 0.6%, 75.3%, 12.5% and 0.4% for men and 0.6%, 9.1%, 1.0%, 72.9%, 15.3% and 0.9% for women respectively. The reasons for these discrepancies could be genetic heterogeneity and gene environment interactions in different ethnic population. It is well known that the ϵ_4 allele of Apo E is associated with increased prevalence of arthrosclerosis and cardiac heart disease (CHD)[20-21]. However there are controversial results concerning the association between Apo E genotypes and some cardiovascular risk factors. Some studies have suggested that high blood pressure may be associated with the presence of the ϵ_4 allele [22-24], while others have found its association with ϵ_2 allele [25]. However no association was found in few studies [25]. In this study we evaluated the distribution of Apo E genotype and alleles in angiographically defined CAD patients and control subjects,

and found these polymorphisms as risk factors for atherosclerosis. As it shown, the distribution of ϵ_4/ϵ_4 , ϵ_2/ϵ_3 , ϵ_3/ϵ_3 , genotypes and ϵ_3 and ϵ_4 alleles in patients group were significantly different from control group. It is suggested that the ϵ_4 allele and ϵ_2/ϵ_3 genotype of Apo E may be less efficient at retarding the oxidation of LDL than others. As it shown in Tables 1 the prevalence of ϵ_3/ϵ_3 genotype was 1.5 fold high in control group when compared with patients (51% Vs 34%, $p=0.015$) whereas prevalence of ϵ_4/ϵ_4 and ϵ_2/ϵ_3 genotypes was 2 and 2.25 fold high in patient group than control subjects (30% Vs 15%, $p=0.01$ and 18% Vs 8%, $p=0.036$). This finding suggests that the prevalence of ϵ_4/ϵ_4 and ϵ_2/ϵ_3 genotypes may be risk factors in this complex disease. The frequency of ϵ_3 allele was 1.5 fold high in control group when compared to patient (51% Vs 34%, $p=0.015$, $\chi^2=5.9$, $OR=0.44$), while statistically difference was found between patients and controls with respect to ϵ_2 allele frequency (32% Vs 28%, $p=0.53$, $\chi^2=0.38$, $OR=1.2$). It is suggested that ϵ_2 allele may be a risk factor for CAD disease in Iranian population. A significant difference was found between the prevalence of ϵ_4 allele in patient group as comparison with control subjects (34% Vs 21%, $p=0.04$, $\chi^2=4.23$, $OR=2$). These results showed an evidence of an association between the ϵ_2 and ϵ_4 alleles and CAD. This finding is accordance or different to some studies that performed in different population with coronary artery disease. These findings are accordance to the results of two meta-analysis [26a]. The results of these study showed that the odd ratios (ORs) for coronary heart disease (CHD) in ϵ_2 and ϵ_4 alleles versus persons had with ϵ_3 allele. Compared with those who had the ϵ_3 allele, the pooled ORs for CHD among carriers of ϵ_4 allele were 1.3 in the classic random effects model and 1.42 in the bayesian hierarchical random effect mode. These two model showed that no evidence of association between the ϵ_2 allele and CHD risk (Ors= 0.93 and 0.98) respectively [26]. They showed a similar estimates for each of ϵ_2/ϵ_2 , ϵ_2/ϵ_3 , ϵ_2/ϵ_4 , ϵ_3/ϵ_4 and ϵ_4/ϵ_4 genotypes compared with ϵ_3/ϵ_3 genotype in both classic random- effects model and a bayesian hierarchical random effect model. They showed that persons with ϵ_3/ϵ_4 and ϵ_4/ϵ_4 genotypes had higher risk for CHD (ORs =1.41 and 1.36) respectively than those with the ϵ_3/ϵ_3 genotype, whereas there was no evidence of any association between CHD risk and ϵ_2/ϵ_2 , ϵ_2/ϵ_3 genotypes (ORs = 0.43, 1.04 and 1.11) respectively. The results of our study with respect to ϵ_4 allele carriers are accordance to two meta analysis studies results.

In a study by Bhavani et al [27] the prevalence of genotypes and allele frequencies among hypertension patients and controls were identified. They showed that prevalence of ϵ_3/ϵ_4 genotypes was 1.5 fold high in patients when compared to controls (14.5% Vs 10.0 %, $p \leq 0.05$) while prevalence of ϵ_2/ϵ_3 genotype was high in controls than in patients (6.5% Vs 4.3%). They showed that statistically significant difference was not found between patients and controls with respect to ϵ_2 and ϵ_3 allele frequencies, while ϵ_4 allele frequency was found to be more prevalent in patients (12.16%) than in controls (5.75%, $\chi^2=10.87$, $p=0.05$). They found that this allelic association should higher relative incidence of ϵ_4 allele ($\chi^2=9.13$, $p=0.05$) as compared to other alleles and also in case with family history of hypertension ($\chi^2=6.79$, $p \leq 0.05$). Analysis of the

apolipoprotein E gene polymorphism in large Caucasian population by Hubacle et al [28], the carrier of mutant allele Arg 136 / Ser in C Zech region was identified. They estimated that the population frequency of this Apo E mutation is very low. They suggested that this mutation in subjects not necessarily connected with elevated lipid in all cases. In present study the mutant allele (Arg 136 Ser) in Iranian population was not found. The results of a study by Merho [29] showed that Apo E polymorphism had a significant effect on lipid levels in Koreans, that the association between the Apo E allele type and HDL-C was modified by age in women, and that the association between the Apo E allele and triglyceride levels was modified by smoking status in men [29]. These findings high light the important effect of gene-environment interaction on lipid levels. They showed that the carrier of the Apo ϵ^*/ϵ_2 (ϵ_2) allele had a significant total cholesterol and LDL-C concentrations than carrier of the Apo ϵ^*/ϵ_3 (ϵ_3) or ϵ^*/ϵ_4 (ϵ_4) alleles, regardless of gender [29]. It is proposed that the context dependency of Apo E polymorphism and associated effects have been demonstrated suggesting other genetic components to be equally important, and lifestyle including dietary habits are now recognized factors that can either mask or expose an effect of a specific Apo E genotype [30-32]. It is suggested that the association between Apo E polymorphism and different lipoproteins (Triglyceride-HDL-C and LDL-C) levels are not entirely similar among different populations. Gene – environment interaction may contribute to the discrepancies observed between studies. Previous studies have shown that HDL-C levels vary with physical activity, alcohol consumption and diet [33-34]. Reznik et al [35] showed that the association between and Apo E polymorphism postprandial triglyceride clearance was modified by age, bodyweight and triglyceride pool level. As shown by Alessandro [36] in young adults, the Apo ϵ_4 allele and cigarette smoking act synergistically increasing an individual's propensity to have a cerebral ischemic event. However the mechanism underlying of Apo E polymorphism to CHD risk is not completely understood and deserves further investigation. Although the impact of Apo E polymorphism on plasma levels of total and low density lipoprotein cholesterol, apolipoprotein B and apolipoprotein E is well established, the triglycerides, high –density lipoprotein cholesterol, apolipoprotein A-1 and lipoprotein (a) remain equivocal [37-39]. It has been suggested that the ϵ_4 allele is related to HDL-C and LDL-C levels, while the potential antiatherogenic of the ϵ_2 involving lower levels of LDL-C may be offset by accumulation of atherogenic large very low density lipoprotein cholesterol and remnant rich lipoproteins [37-39]. Beyond the effect on lipid metabolism, Apo E genotypes may also affect CHD risk though antioxidative, inflammatory and immune activities [37-39].

In conclusion, our results support the notion that a significant association of ϵ_4 allele is observed with coronary heart disease (CHD) in addition to the other well known risk factors and positive family history. Carriers of ϵ_4 allele form a high risk group showing greater susceptibility to CHD while the ϵ_2 allele has no effect. Further, this observation interplay between genetic and environmental factors must be thoroughly considered in order to evaluate the etiological role

of Apo E in CHD. There is convincing evidence that the relationship between Apo E genotype and plasma lipoprotein lipid levels is context –dependent, being significantly influenced by age [40] and sex [41-42]. Some evidence [43-44] also indicates that the responses of plasma lipoprotein – lipid levels to different lipid lowering interventions may be affected by an individual's Apo E genotype, indicating the significance of gene-environment interactions.

ACKNOWLEDGMENT

This study was supported in part by a grant from the Iran University of Medical Sciences. The authors wish to thank research deputy of University for funding of this project and thank Shahid Rajaei in the north of Tehran for providing the samples.

REFERENCES

- [1] Mahley RW. Apo lipoprotein E: cholesterol transport protein with expanding role in cell. *Science*, 1988; 240: 622-630.
- [2] Siest G, Pillot T, Regis – Bailly A, Leininger – Muller B, Steinmetz J and Galteau MM. Apolipoprotein E : An important gene and protein to follow in laboratory medicine. *Clin-Chem* 1995; 41: 1068-1086.
- [3] Paik YK, Chang DJ, Reardon CA, Davies GE, Mahle RW and Tayler JM. Nucleotide sequence and structure of the human apolipoprotein E gene. *Proc Natl Acad Sci USA* 1985; 82: 3445-3449.
- [4] Das HK, McPherson J, Bruns GA, Karathasis SX and Breslow JL. Isolation characterization and mapping to chromosome 19 of the human apolipoprotein E gene. *J Biol Chem* 1985; 60: 6240-6247.
- [5] Smith M, Vonder Kooij- Meijis E, Frants RR, Havekes L and Klasen EC. Apolipoprotein gene cluster on chromosome 19: Definite localization of the top C2 gene and the polymorphic Hha I site associated with type 1 hyperlipoproteinemia. *Hum Genet*. 1988; 78: 90-93.
- [6] Ilveskoski G, Perola N and Lethimalei J. Age dependent association of apolipoprotein E genotype with coronary and aortic atherosclerosis in middle –aged men an autopsy study. *Circulation* 1999; 100: 608-813.
- [7] Utermann G, Largen beek U, Beisiegel U and weber W. Genetics of the apolipoprotein E system in men. *Am J Hum Genet*, 1982; 32: 339-347.
- [8] Breslow JL. Apolipoprotein genetic variation and human disease. *Physiol. Rev.* 1988; 68: 85-98.
- [9] Hallman DM, Boerwinkle E, Sandholzer C, Menzei HJ and Csazar A. The apolipoprotein E polymorphism; a comparison of allele frequencies and effects in nine populations. *Am J Hum Genet*, 1991; 49: 338-349.
- [10] Boerwinkle E, Visvikis S, Weisn D, Steinmetz J, Hanash Sm and Sing Cf. The use of measured genotype information in the analysis of quantitative phenotypes in man: The role of the apolipoprotein E polymorphism in determining levels, variability and co- variability of cholesterol, betalipoprotein and triglycerides in a sample of unrelated individuals. *Am J Med Genet*, 1987; 27: 567-582.
- [11] Davignon J. Apolipoprotein E polymorphism and atherosclerosis. In. *Born Gvr Schwatz Cy. (Cds). New Horizons in coronary heart disease. Curr. Sci.* 1993; 5: 5.1-5.21.
- [12] Genovefa O, Kolovou , Katherimek A and nagnostopoulou . A polipoprotein E polymorphism age and coronary heart disease. *Ageing Research reviews*. 2007; 6: 94-108.
- [13] Cord EH, Sauders AM. Gene dose of apolipoprotein E type allele 4 and the risk of alzheimer's disease in late onset families. 1993; 13: 261(5123) 828-829.
- [14] Yilman M. Hemostatic markers and renal function after cardiopulmonary bypass. *Asian Cardiovasc Thrac Ann* 2001; 9: 86-89.
- [15] Miller SA, Dykes DD and Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. *Nucleic acid Res* 1988; 16: 1215-1218.
- [16] Hixson JE and Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with Hha I. *J lipid Res.* 1990; 31: 545-548.
- [17] Eichner Je, Dunn T, Perveen G, Thompson DM, Stewart RE and Strohla BC. Apolipoprotein E polymorphism and cardiovascular disease a huge review. *AM J Epidem.* 2003; 155: 487-495.
- [18] Breslow JC. Apolipoprotein genetic variation and human disease. *Physiol. Rev.* 1988; 68: 85-98.
- [19] Ventakaramana P, Chengal RE and Ferrell RE. Apolipoprotein E polymorphism in two populations of Andru Pradesh. *Ind J Hum Genet* 2002; 3: 1-5.
- [20] Utermann G, Hardewing A and Zimmer F. Apolipoprotein E phenotypes in patients with myocardial infarction. *Hum Genet.* 1984; 65: 237-241.
- [21] Lehtinen Lehtimalci T, Sisto, Salenius TP, Mikkila M and Jakela H. Apolipoprotein E polymorphism, serum lipid, myocardial infarction and severity of angiographically verified coronary datery disease in men and women. *Atherosclerosis*; 1995; 114: 83-91.
- [22] Dembinska Kiee A, Kawecka- Jaszez K, Kwasniak M, Gaevaro I, Pankiewicz J and Maiczewsia Maleec M. Apo E isoforms , insulin out put and plasma lipid levels in essential by hypertension. *Eur J Clin Invest*, 1998; 28: 95-99.
- [23] Yilmas H, Isbir J, Agachan B and Aydin M. Is epsilon 4 allele of apolipoprotein E associated with more severe end stage in essential hypertension? *Cell Biochem. Funct* 2001; 19: 191-195.
- [24] Li X, Duy, DUY and Huang X. Association of apolipoprotein E gene polymorphism with essential hypertension and its complication. *Clin Exp Med.* 2003; 2: 175-179.
- [25] Couderc R, Mahleumof, Bailieu S, Fencon G, Mary R, Fernalden J. Prevalence of apolipoprotein E phenotypes in ischemic cerebrovascular disease. *Stroke* 1993; 24: 661-664.
- [26] Yiaqing S, Meir J, Stampher . Apolipoprotein E Genotypes Coronary Heart Disease. *Annals of Internal Medicine* 2004; 141: 137-147.
- [27] Bharani AB, Sastry KB, Krishna Reddy N and Padma T. Lipid profile and apolipoprotein E polymorphism in essential hypertension. *Indian Heart J* 2005; 57: 1115-1117.
- [28] Hubacok JA, Adamakovu V and Skodova I. *Phisol Res.* 2005; 54: 573-582.
- [29] Merho Shin, Hce Nsm Kim, Lian- Hua Coul Sun- Song, Kwoon, Kjaooag- Soopark, Heam-Heo, Churg, Jin-Sn. *J Korean Med Sci* 2003; 20: 361-366.
- [30] Dallongeville J, Lussier Caean S and Darignon J. Modulation of plasma triglyceride levels by apo E phenotype: a meta analysis. *J lipid Res.* 1992; 33: 447-454.
- [31] Simopoulou AP. Genetic variation and nutrition. *Word Rev Nutr Diet.* 1999; 84: 118-140.
- [32] Knijff P, Havefes LM. Apolipoprotein E as a risk factor for coronary heart disease: a genetic and molecular biology approach *Curr Opin Lipid* 1996; 7: 59-63.
- [33] Luss, W, Bolduc A, Auigness M, Niyonsengu T and Sing CF. Effect of alcohol in take of lipid metabolism depends on *Tmunb Ratc Fial* 2002; 22: 1824-1831.
- [34] Nucklus BJ, Ferrull Re, Bunjaul LB, Berumun DM and Dennis KE Gold- bery AP. Effect of apolipoprotein E genotype on dietary- induced changes in high density lipoprotein cholesterol in obese postmenopause women. *Metabolism* 2002; 51: 853-858.
- [35] Reznik Y, Merallo R, Poosse P, Mahoudeau J and Fradins. The effect of age body mass index and fasting triglyceride level on postprandial lipemia is dependet on opolipoprotein E polymorphism in subjects with non-insulin dependent diabetes. *Metabolism* 2002; 51: 1088-1092.
- [36] Andrade DE, Thandi M, Brown S, Gaho A, Patsch W and Boerwinke E. Relationship of the apolipoprotein E gene and early carotide atherosclerosis defined by ultrasonography in asymptomatic adults. *Arterioscler Thromb Vasc Biol* 1997; 9: 91-97.
- [37] Lusis A, Mar Rand J and Pajakanta P. Genetics of atherosclerosis. *Anna Rev. Genomics Hum. Genet.* 2004; 5: 184-218.
- [38] Dallongevill J, Lussier-Cacan S and Davignon J. Modulation of plasma triglyceride levels by apo E phenotype: a meta –analysis. *J Lipid Res.* 1992; 33: 447-454.
- [39] Davignon J, Cohn JS, Mabile L and Bernier L. Apolipoprotein E and atherosclerosis : insight from animal and human studies. *Clin Chim Acta* 1999; 286- 115-43.
- [40] Davignon J, Gregg RE and Sing CF. Apolipoprotein E polymorphism and atherosclerosis. *Arteriosclerosis* 1988; 8: 1-21.
- [41] Zerbe KE, Ferrell Rm and Sing CF. Genotype-environment interaction: apolipoprotein E gene effects and gene as an index of time and spatial context in humans. *Genetics* 1996; 143: 463-478.

- [42] Reilly S, Ferrell R, Kottke B and Sing CF. The gender- specific apolipoprotein E genotype influence on the distribution of lipids and apolipoproteins in the population of Rochester, MN. 11. Regression relationships with concomitants. *Am J Hum Genet* 1992; 51: 1311-1324.
- [43] Reilly S, Ferrell R and Sing CF. The gender –specific apolipoprotein E genotype influence on the distribution of lipids and apolipoproteins in the population of Rochester, MN. 111. Correlations and covariances. *Am J Hum Genet* 1994; 55: 1001-1018.
- [44] Coats AJ. Ethical authorship and publishing. *Int J Cardiol* 2009; 131: 149-50.